US Markets
Home›US Markets›IPOs›Sanofi reviews Insmed acquisition.
Sanofi reviews Insmed acquisition.
Insmed stock rose after report.
Insmed Inc. shares increased following information that Sanofi SA is evaluating a possible takeover. The pharmaceutical giant seeks new growth avenues to lessen dependence on Dupixent. Insmed generates revenue from two respiratory medications: Brinsupri and Arikayce.
Brinsupri reported $400.1 million in third-quarter sales, while Arikayce brought in $124.4 million. Insmed anticipates $1.35 billion to $1.4 billion in Brinsupri revenue and $460 million to $470 million in Arikayce sales for 2026. The company also develops treprostinil palmitil inhalation powder for lung conditions.